Abstract
Purpose
To study the apoptotic effect of the 2-phenylaminopyrimidine derivative STI571 in combination with antioxidant agents on K-562 cell line derived from a Philadelphia chromosome-positive chronic myeloid leukemia patient.
Materials and methods
K-562 (BCR/ABL+), U-937, and HL60 (BCR/ABL−) leukemic cell lines were incubated with STI571 and the antioxidant agents catalase, glutathione, superoxide dismutase, and amifostine (AMI). Apoptotic effect was analyzed by morphological and flow cytometric criteria.
Results
STI571 at concentrations higher than 0.25 μmol L−1 produced apoptosis (P<0.05) in K-562 cells only after treatment for 72 h. At the mentioned concentrations, STI571 also induced an increase in the loss of mitochondrial transmembrane potential from 24.6 to 40%. Combination of STI571 (0.5 μmol L−1) with antioxidant agents showed that the cytoprotective agent AMI (0.75 mg mL−1) produced an additive effect in the proapoptotic activity of STI571 in K-562 cells at nuclear (58.8%±2.0 vs. 28.9%±3.3) and mitochondrial (53.3%±3.6 vs. 29.5%±1.2) levels.
Conclusions
Our results show that only AMI in combination with STI571, at submicromolar concentration, has an additive effect in K-562 cell line, and it does not have severe toxic effects on Philadelphia chromosome negative cells.
Similar content being viewed by others
Abbreviations
- AlloBMT:
-
Allogeneic bone-marrow transplantation
- AMI:
-
Amifostine
- ATP:
-
Adenosine triphosphate
- BC:
-
Fatal blastic phase
- BCR/ABL−:
-
BCR/ABL negative cells
- BCR/ABL+:
-
BCR/ABL positive cells
- CA:
-
Continuous administration
- CAT:
-
Catalase
- CML:
-
Chronic myeloid leukemia
- CP:
-
Chronic phase
- ΔΨm:
-
Mitochondrial transmembrane potential
- DMSO:
-
Dimethyl sulfoxide
- EDTA:
-
Ethylenediaminetetraacetic acid
- GSH:
-
Glutathione
- HDC:
-
Highly damaged cells
- IFN:
-
Interferon
- LMA:
-
Low-melting agarose
- MDC:
-
Middle damaged cells
- PBS:
-
Phosphate-buffer solution
- PI-3k:
-
Phosphatidylinositol-3 kinase
- PMN:
-
Polymorphonuclear cells
- Rh123:
-
Rhodamine 123
- RNAse A:
-
Ribonuclease A
- ROS:
-
Reactive oxygen species
- SOD:
-
Superoxide dismutase
- STI571:
-
2-Phenyaminopyrimidine derivative
- UC:
-
Undamaged cells
References
Cortes JE, Talpaz M, Kantarjian H (1996) Chronic myelogenous leukemia: a review. Am J Med 100:555–570
Rowley JD (1973) A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290–293
Rosti V, Bergamaschi G, Ponchio L, Cazzola M (1992) c-Abl function in normal and chronic myelogenous leukemia hematopoiesis: in vitro studies with antisense oligomers. Leukemia 6:1–7
Evans C, Owen-Lynch P, Whetton AD, Dive C (1993) Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells. Cancer Res 53:1735–1738
Bedi A, Barber JP, Bedi GC, El-Deiry WS, Sidransky D, Vala MS, Akhtar AJ, Hilton J, Jones RJ (1995) BCL-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 86:1148–1158
Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM (1999) The biology of chronic myeloid leukemia. N Engl J Med 341:164–172
Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340:1330–1340
Klejman A, Rushen L, Morrione A, Slupianek A, Skorki T (2002) Phosphatidylinositol-3 kinase inhibitors enhance the antileukemia effect of STI571. Oncogene 21:5868–5876
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger F, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001a) Efficacy and safety of a specific inhibitor of the BCR/ABL tyrosine kinase in chronic myeloid leukaemia. N Engl J Med 344:1031–1037
Druker BJ, Sawyers CL, Kantarjian H, Resta D, Fernandes Reese RNS, Ford JM, Capdeville R, Talpaz M (2001b) Activity of a specific inhibitor of the BCR/ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038–1042
Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645–652
Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV (2000) Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96:1070–1079
Topaly J, Fruehauf S, Ho AD, Zeller WJ (2002) Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning. Br J Cancer 86:1487–1493
Tabrizi R, Mahon FX, Cony Makhoul P, Lagarde V, Lacombe F, Berthaud P, Melo JV, Reiffers J, Belloc F (2002) Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571. Leukemia 16:1154–1159
Sattler M, Verma S, Shrinkhande G, Byrne CH, Pride YB, Winkler T, Greenfield EA, Salgia R, Griffin JD (2000) The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 275:2473–2478
Lozzio CB, Lozzio BB (1975) Human chronic myelogenous leukemia cell line with positive Philadelphia chromosome. Blood 45:321–334
Sato EF, Higashino M, Ikeda K, Wake R, Matsuo M, Utsumi K, Inoue M (2003) Oxidative stress-induced cell death of human oral neutrophils. Am J Physiol Cell Physiol 284:1048–1053
Romano M, Lamberti A, Bisogni R, Garbi C, Pagnano A, Auletta P, Tassone P, Turco M, Venuta S (1999) Amifostine inhibits hematopoietic cell apoptosis by activating NF-κB/Rel transcription factors. Blood 94:4060–4066
Buschini A, Alessandrini Ch, Martino A, Pasini L, Rizzoli V, Carlo-Stella C, Poli P, Rossi C (2002) Bleomycin genotoxicity and amifostine (WR-2721) cell protection in normal leukocytes vs. K562 tumoral cells. Biochemical Pharmacology 63:967–975
Druker BJ (2003) Chronic myeloid leukemia in the imatinib era. Semin Hematol 40:1–3
Oetzel C, Jonuleit T, Götz A, van der Kuip H, Michels H, Duyster J, Hallek M, Aulitzky WE (2000) The tyrosine kinase inhibitor CGP 57148 (STI 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X1. Clin Cancer Res 6:1958–1968
Gambacorti-Passerini C, le Coutre P, Mologni L, Fanelli M, Bertazzoli C, Marchesi E, Di Nicola M, Biondi A, Corneo GM, Belotti D, Pogliani E, Lidon NB (1997) Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL + leukemic cells and induces apoptosis. Blood Cells Mol Dis 23:380–394
Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Nagesh Rao P, Sawyers CL (2001) Clinical resistance to STI571 cancer therapy caused by BCR/ABL gene mutation or amplification. Science 293:876–880
Capizzi R (1996) Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol 4:2–17
Lee EJ, Gerhold M, Palmer MW, Christen RD (2003) p53 protein regulates the effects of amifostine on apoptosis, cell cycle progression, and cytoprotection. Br J Cancer 88:754–759
Shaw LM, Bonner H, Lieberman R (1996) Pharmacokinetic profile of amifostine. Semin Oncol 23 (Suppl 8):18–22
Poloni A, Leoni P, Curzi L, Cantori I, Mancini S, Montanari M, Masia MC, Olivieri A (1999) Ex vivo purging of leukapheresis collections with nitrogen mustard: amifostine pretreatment improves both early and late pheripheral blood progenitor cell recovery. Exp Hematol 27:1548–1556
Douay L, Hu C, Giarratana M-C, Gorin N-C (1995) Amifostine (WR-2721) protects normal haematopoietic stem cells against cyclophosphamide derivatives’ toxicity without compromising their antileukaemic effects. Eur J Cancer 31a (Suppl 1): s14-s16
Sneed TB, Kantarjian HM, Talpaz M, O’Brien S, Rios MB, Bekele BN, Zhou X, Resta D, Wierda W, Faderl S, Giles F, Cortes JE (2004) The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer100:116–121
Blasiak J, Gloc E, Mlynarski W, Drzewoski J, Skórski T (2002) Amifostine differentially modulates DNA damage evoked by idarubicin in normal and leukemic cells. Leukemia Res 26:1093–1096
Acknowledgments
This paper was supported by grants from CONICET, ANPCyT, and Academia Nacional de Medicina.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vellón, L., González-Cid, M., Nebel, M.d.C. et al. Additive apoptotic effect of STI571 with the cytoprotective agent amifostine in K-562 cell line. Cancer Chemother Pharmacol 55, 602–608 (2005). https://doi.org/10.1007/s00280-004-0952-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-004-0952-5